ERBB3 and neoplasm: Importantly, this study describes the dose-dependent inhibition of tumor uptake of 89Zr-mAb by unlabeled mAb confirming target engagement, that is, specific binding and internalization of anti-HER3 antibody by HER3 receptors in tumor tissues.